Back to search results

CPAP Trial for Bronchopulmonary Dysplasia (BPD)

This study, called the CPAP Trial, is looking at whether continuing a breathing support called CPAP (Continuous Positive Airway Pressure) for a longer time can help prevent a lung condition called Bronchopulmonary Dysplasia (BPD) or death in premature babies. Researchers want to see if extending CPAP until 34 weeks after conception, or for at least two extra weeks, is better than gradually switching to a nasal cannula (a small tube that delivers oxygen). This study is for babies born before 29 weeks of pregnancy who are currently on CPAP and meet certain stability requirements. The main goal is to see if there's a difference in BPD or death by 36 weeks after conception. The study aims to enroll 860 babies.

Study design
This is an interventional study comparing two different breathing support strategies. It plans to enroll 860 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed until 36 weeks' postmenstrual age (PMA) to assess for bronchopulmonary dysplasia or death.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07417111

Continued Pressure for Alveolar Protection (CPAP Trial)

Recruiting
NAUp to 31InterventionalPrevention
NICHD Neonatal Research Network
~860 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:CPAPNasal Cannula

At a glance

Recruiting sites
15 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Bronchopulmonary Dysplasia or Death
Measured over 36 Weeks' PMA

Conditions

Bronchopulmonary Dysplasia (BPD)

Explore related trials

Bronchopulmonary Dysplasia

Where it's being run

15 sites across 12 states
California2
Ohio2
Texas2
Alabama1
Georgia1
Illinois1
Iowa1
Mississippi1

Study leadership

  • Colm P. Travers, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Colm P. Travers, MD
[email protected]
205-934-3100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Gestational age \<29 weeks at birth
PMA \<32 weeks at study entry
On treatment with CPAP without a rate in FiO2 \<0.25 and PEEP of 4-5 cmH2O
Meet stability criteria:
If previously intubated must be extubated ≥ 72 hours
\<3 self-resolving apneas (≤ 20 s) and/or bradycardia (\<100 bpm) in any hour over previous 6 hours
No episodes of apnea or bradycardia requiring intervention (oxygen/stimulation/bag and mask) for 24 hours
Parents/legal guardians consent for enrollment

Exclusion

Major malformation
Neuromuscular condition that affects respiration
Terminal illness
Decision to withhold or limit support
Too sick to participate in opinion of Attending physician
Clinical shock, sepsis
Planned surgery during study period

What this trial measures

  • Bronchopulmonary Dysplasia or Death36 Weeks' PMA

    The likelihood of BPD or death at 36 weeks' Postmenstrual Age (PMA): a five-level ordinal outcome (death, survival with grade 3 BPD, survival with grade 2 BPD, survival with grade 1 BPD, and survival free of any BPD).